Prasad 2013.

Methods	Single‐centre placebo RCT
Participants	Participants randomised to 1 of 2 groups (n = 62) ‐ Mifepristone 10 mg ‐ Placebo Inclusion criteria ‐ Symptomatic fibroids No additional details available Setting: Delhi, India
Interventions	Mifepristone 10 mg orally daily vs placebo Duration: 3 months
Outcomes	Outcomes assessed at baseline and at 3 months Primary outcome ‐ Fibroid volume Secondary outcomes ‐ Endometrial biopsy. Reported on 'cystic glandular hyperplasia' but pathology criteria not available ‐ Hormone profile ‐ Fibroid symptoms ‣ Bleeding/amenorrhoea ‣ Dysmenorrhoea
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Randomized" ‐ no details. Attempts to contact study authors unsuccessful
Allocation concealment (selection bias)	Unclear risk	Not stated. Attempts to contact study authors unsuccessful
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	"Single blind" ‐ no further details. Attempts to contact study authors unsuccessful
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	"Single blind" ‐ no further details. Attempts to contact study authors unsuccessful
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No details. Attempts to contact study authors unsuccessful
Selective reporting (reporting bias)	Unclear risk	No details. Attempts to contact study authors unsuccessful
Other bias	Unclear risk	Data in form of conference proceedings. No published follow‐up data. Protocol not found on clinicaltrials.gov